Nerviano Medical Sciences S.r.l. to Present at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
NMS-153: A clinical-phase, potent and highly selective small molecule inhibitor of Monopolar Spindle 1 with differentiated mechanism of action and potential for First in Class/Best in Class
Nerviano, 15 May 2023 – Nerviano Medical Sciences Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that a poster, describing the currently enrolling phase II part of the trial MPSA-153-001, will be presented at the upcoming ASCO Annual Meeting which will be held June 2-6, 2023 at the McCormick Place, Chicago, IL.
Title: “Phase II study on safety and efficacy of NMS-01940153E, an MPS1 inhibitor with first-in-class potential, in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy”
Session Category: Trials in Progress (TIP); Poster Session – Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Abstract Number: TPS4185
Date and Time: Monday, June 5, 2023, 8:00 AM-11:00 AM (CDT)
link: 20230515 MPS1 2023 ASCO poster_PressRelease
from NMSGroup
